Merrill Lynch placed a “buy” rating on the maker of generic drugs, highlighting the company’s mix of niche pharmaceuticals products, diverse revenue base, and low product-concentration risk, Dow Jones reported. As a small company operating in the generic injectables and ophthalmology niches, AKRX is well positioned to expand its revenue and per-share earnings, Merrill Lynch said.